SG194717A1 - High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain - Google Patents
High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain Download PDFInfo
- Publication number
- SG194717A1 SG194717A1 SG2013080718A SG2013080718A SG194717A1 SG 194717 A1 SG194717 A1 SG 194717A1 SG 2013080718 A SG2013080718 A SG 2013080718A SG 2013080718 A SG2013080718 A SG 2013080718A SG 194717 A1 SG194717 A1 SG 194717A1
- Authority
- SG
- Singapore
- Prior art keywords
- peptide
- analogue
- inhibitors
- psd
- linker
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 208000002193 Pain Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000006931 brain damage Effects 0.000 title 1
- 231100000874 brain damage Toxicity 0.000 title 1
- 208000029028 brain injury Diseases 0.000 title 1
- 239000004090 neuroprotective agent Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract 2
- 108700019745 Disks Large Homolog 4 Proteins 0.000 abstract 2
- 102000047174 Disks Large Homolog 4 Human genes 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 abstract 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000318 excitotoxic Toxicity 0.000 abstract 1
- 230000003492 excitotoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161485898P | 2011-05-13 | 2011-05-13 | |
| EP11165994 | 2011-05-13 | ||
| PCT/EP2012/058762 WO2012156308A1 (en) | 2011-05-13 | 2012-05-11 | High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG194717A1 true SG194717A1 (en) | 2013-12-30 |
Family
ID=44367299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013080718A SG194717A1 (en) | 2011-05-13 | 2012-05-11 | High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2707014B1 (https=) |
| JP (1) | JP6084207B2 (https=) |
| KR (1) | KR102046830B1 (https=) |
| CN (1) | CN103533949B (https=) |
| AU (1) | AU2012257774C1 (https=) |
| BR (1) | BR112013029206B1 (https=) |
| CA (1) | CA2833515C (https=) |
| DK (1) | DK2707014T3 (https=) |
| ES (1) | ES2544573T3 (https=) |
| IL (1) | IL228893B (https=) |
| PL (1) | PL2707014T3 (https=) |
| SG (1) | SG194717A1 (https=) |
| WO (1) | WO2012156308A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014356912B2 (en) | 2013-12-01 | 2019-08-01 | University Of Copenhagen | Fatty acid derivatives of dimeric inhibitors of PSD-95 |
| CN103804500B (zh) * | 2014-01-22 | 2015-12-30 | 广州军区广州总医院 | 用于治疗慢性疼痛的多肽 |
| CN106661126B (zh) * | 2014-05-28 | 2021-12-10 | 诺诺公司 | TAT-NR2B9c的氯盐 |
| BR112020000115A2 (pt) * | 2017-07-05 | 2020-07-07 | Biocells (Beijing) Biotech Co., Ltd. | sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos |
| JP7073486B2 (ja) | 2017-09-30 | 2022-05-23 | ▲拝▼西欧斯（北京）生物技▲術▼有限公司 | 興奮性神経毒性に関連した損傷の治療用ペプチド組成物 |
| CA3089161A1 (en) * | 2018-02-02 | 2019-08-08 | Kobenhavns Universitet | Compounds for the treatment of acute brain injury |
| CN110627877A (zh) * | 2019-09-25 | 2019-12-31 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
| CN110787284A (zh) * | 2019-11-23 | 2020-02-14 | 胡书群 | 一种治疗缺血性脑损伤的混合小肽tat-shc及其应用 |
| WO2021119756A1 (en) * | 2019-12-20 | 2021-06-24 | PYC Therapeutics Limited | Novel cellular delivery methods |
| CN111285923B (zh) * | 2020-03-05 | 2023-02-03 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
| US20230346948A1 (en) * | 2020-03-06 | 2023-11-02 | University Of Copenhagen | Lipid conjugated peptide inhibitors of PICK1 |
| CA3203688A1 (en) * | 2021-01-08 | 2022-07-14 | Jonathan David Garman | Plasmin-resistant peptides for improved therapeutic index |
| TW202306965A (zh) | 2021-05-12 | 2023-02-16 | 哥本哈根大學 | Ｐｓｄ－９５抑制劑及其用途 |
| CN114533874B (zh) * | 2022-01-27 | 2023-12-29 | 北京和舆医药科技有限公司 | Psd-95 gk结构域作为神经保护靶点的用途 |
| EP4706670A1 (en) * | 2023-04-26 | 2026-03-11 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Psd-95 domain inhibitor, and preparation method therefor and use thereof |
| CN119569824A (zh) * | 2023-09-07 | 2025-03-07 | 湖南中晟全肽生物科技股份有限公司 | 作为神经保护剂的药用化合物及其应用 |
| CN118027156B (zh) * | 2023-09-07 | 2024-11-05 | 湖南中晟全肽生物科技股份有限公司 | 一种psd-95抑制剂及其用途 |
| CN117164725B (zh) * | 2023-09-07 | 2024-05-10 | 湖南中晟全肽生物科技股份有限公司 | 一种突触后密度蛋白-95抑制剂多肽 |
| WO2025215348A1 (en) * | 2024-04-08 | 2025-10-16 | The Boots Company Plc | Skin wound treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| EP2089052A4 (en) | 2006-05-24 | 2011-02-16 | Peg Biosciences | POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS |
| WO2008008348A2 (en) * | 2006-07-11 | 2008-01-17 | Arbor Vita Corporation | Method and compositions for treating stroke with fever |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| WO2010004003A2 (en) * | 2008-07-09 | 2010-01-14 | University Of Copenhagen | Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
-
2012
- 2012-05-11 ES ES12720862.7T patent/ES2544573T3/es active Active
- 2012-05-11 DK DK12720862.7T patent/DK2707014T3/en active
- 2012-05-11 CN CN201280023754.8A patent/CN103533949B/zh active Active
- 2012-05-11 CA CA2833515A patent/CA2833515C/en active Active
- 2012-05-11 SG SG2013080718A patent/SG194717A1/en unknown
- 2012-05-11 JP JP2014510747A patent/JP6084207B2/ja active Active
- 2012-05-11 WO PCT/EP2012/058762 patent/WO2012156308A1/en not_active Ceased
- 2012-05-11 PL PL12720862T patent/PL2707014T3/pl unknown
- 2012-05-11 EP EP12720862.7A patent/EP2707014B1/en active Active
- 2012-05-11 KR KR1020137031532A patent/KR102046830B1/ko active Active
- 2012-05-11 AU AU2012257774A patent/AU2012257774C1/en active Active
- 2012-05-11 BR BR112013029206-7A patent/BR112013029206B1/pt active IP Right Grant
-
2013
- 2013-10-15 IL IL228893A patent/IL228893B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013029206A2 (pt) | 2017-02-14 |
| AU2012257774C1 (en) | 2016-11-03 |
| CA2833515A1 (en) | 2012-11-22 |
| EP2707014A1 (en) | 2014-03-19 |
| CA2833515C (en) | 2017-11-28 |
| EP2707014B1 (en) | 2015-06-17 |
| KR102046830B1 (ko) | 2019-11-20 |
| AU2012257774B2 (en) | 2016-07-28 |
| BR112013029206B1 (pt) | 2021-05-04 |
| CN103533949A (zh) | 2014-01-22 |
| KR20140038435A (ko) | 2014-03-28 |
| IL228893B (en) | 2018-01-31 |
| IL228893A0 (en) | 2013-12-31 |
| JP2014514365A (ja) | 2014-06-19 |
| AU2012257774A1 (en) | 2013-11-07 |
| CN103533949B (zh) | 2015-11-25 |
| PL2707014T3 (pl) | 2015-12-31 |
| WO2012156308A1 (en) | 2012-11-22 |
| ES2544573T3 (es) | 2015-09-01 |
| DK2707014T3 (en) | 2015-09-14 |
| JP6084207B2 (ja) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG194717A1 (en) | High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain | |
| MX339993B (es) | Inhibidores dimericos de alta afinidad de psd-95 como neuroprotectores eficientes contra daño isquemico cerebral y para el tratamiento de dolor. | |
| CL2013003406A1 (es) | Compuestos derivados de dolastatina unidos a aminoacidos no naturales; procedimiento de preparacion; composiciones farmaceuticas, útiles en el tratamiento del cancer de mamas. | |
| SG10201810154WA (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| EP2390265A3 (en) | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | |
| MY171146A (en) | Compositions of glp-1 peptides and preparation thereof | |
| BRPI1014508A2 (pt) | análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso" | |
| PH12013501927A1 (en) | Nutritional compositions comprising alpha-hydroxyisocaproic acid | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| CO2017008862A2 (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| PH12013501903A1 (en) | Nutritional compositions including branched chain fatty acids for improving gut barrier function | |
| NZ606250A (en) | Methods of inhibition of protein fucosylation in vivo using fucose analogs | |
| UA111357C2 (uk) | Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти) | |
| UA109949C2 (uk) | Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання | |
| JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
| IL209967A (en) | Peptides capable of inducing cytotoxic lymphocyte (ctl), medicinal preparations containing them and their use and in vitro methods of inducing ctl | |
| IL231421A (en) | Lupane and its similar compounds are preserved in position 3ß by carboxy-alkyl-carbonyl-oxy and position 17- by (alkyl-conserved) amino, and also anti-HIV drug preparations containing them | |
| EA201490221A1 (ru) | Производные аминопропандиола, получение и фармацевтические композиции и применение | |
| EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
| WO2013021284A3 (en) | Anti-il-6 vaccine composition | |
| PH12017501444A1 (en) | (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| MD3233862T2 (ro) | Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta | |
| WO2012019428A8 (zh) | 二苯甲醇类衍生物、其制备方法及其在医药上的应用 | |
| WO2011064779A3 (en) | Peptides derived from hiv-1 gp41 transmembrane for t - immunomodulation |